BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M; International epidemiology Databases to Evaluate AIDS (IeDEA) consortium. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis 2019;19:298-307. [PMID: 30744962 DOI: 10.1016/S1473-3099(18)30673-X] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Loiseau C, Brites D, Reinhard M, Zürcher K, Borrell S, Ballif M, Fenner L, Cox H, Rutaihwa LK, Wilkinson RJ, Yotebieng M, Carter EJ, Abimiku A, Marcy O, Gotuzzo E, Avihingsanon A, Zetola N, Doulla B, Böttger EC, Egger M, Gagneux S. HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2020;64:e00782-20. [PMID: 32718966 DOI: 10.1128/AAC.00782-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Sultana ZZ, Hoque FU, Beyene J, Akhlak-Ul-Islam M, Khan MHR, Ahmed S, Hawlader DH, Hossain A. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2021;21:51. [PMID: 33430786 DOI: 10.1186/s12879-020-05749-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Garcia Rivera MV, Aponte A, Ko WW. Coinfection of Tuberculosis in an Undiagnosed HIV, AIDS Patient Presenting With Shortness of Breath, Constitutional Symptoms and Lymphadenopathy. Cureus 2021;13:e15925. [PMID: 34336428 DOI: 10.7759/cureus.15925] [Reference Citation Analysis]
4 Somoskovi A, Salfinger M. How Can the Tuberculosis Laboratory Aid in the Patient-Centered Diagnosis and Management of Tuberculosis? Clin Chest Med 2019;40:741-53. [PMID: 31731981 DOI: 10.1016/j.ccm.2019.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Su W, Ruan YZ, Li T, Du X, Jiang JW, Li RZ. Characteristics of rifampicin-resistant tuberculosis detection in China, 2015-2019. Infect Dis Poverty 2021;10:99. [PMID: 34274020 DOI: 10.1186/s40249-021-00883-8] [Reference Citation Analysis]
6 Edessa D, Adem F, Hagos B, Sisay M. Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies. PLoS One 2021;16:e0261149. [PMID: 34890421 DOI: 10.1371/journal.pone.0261149] [Reference Citation Analysis]
7 Charoenpak R, Santimaleeworagun W, Suwanpimolkul G, Manosuthi W, Kongsanan P, Petsong S, Puttilerpong C. Association Between the Phenotype and Genotype of Isoniazid Resistance Among Mycobacterium tuberculosis Isolates in Thailand. Infect Drug Resist 2020;13:627-34. [PMID: 32158238 DOI: 10.2147/IDR.S242261] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Udwadia ZF, Patel PP, Sharma S, Gupta A, Tornheim JA. Empiric Addition of Quinolones to First-Line Tuberculosis Treatment Is Associated With Increased Odds of XDR-TB. Front Trop Dis 2022;3:779084. [DOI: 10.3389/fitd.2022.779084] [Reference Citation Analysis]
9 Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Nat Commun 2021;12:424. [PMID: 33462224 DOI: 10.1038/s41467-020-20731-x] [Reference Citation Analysis]
10 Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, Dabis F, Davies MA, Duda SN, Malateste K, Nash D, Wools-Kaloustian K, von Groote PM, Egger M. International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. BMJ Open 2020;10:e035246. [PMID: 32414825 DOI: 10.1136/bmjopen-2019-035246] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
11 Francisco C, Lansang MA, Salvana EM, Leyritana K. Multidrug-resistant tuberculosis (MDR-TB) and multidrug-resistant HIV (MDR-HIV) syndemic: challenges in resource limited setting. BMJ Case Rep 2019;12:e230628. [PMID: 31471363 DOI: 10.1136/bcr-2019-230628] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Al-Mutairi NM, Ahmad S, Mokaddas E. Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait. Sci Rep 2021;11:7765. [PMID: 33833390 DOI: 10.1038/s41598-021-87516-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Han WM, Mahikul W, Pouplin T, Lawpoolsri S, White LJ, Pan-Ngum W. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach. PLoS One 2021;16:e0248846. [PMID: 33770104 DOI: 10.1371/journal.pone.0248846] [Reference Citation Analysis]
14 Reichmuth ML, Hömke R, Zürcher K, Sander P, Avihingsanon A, Collantes J, Loiseau C, Borrell S, Reinhard M, Wilkinson RJ, Yotebieng M, Fenner L, Böttger EC, Gagneux S, Egger M, Keller PM. Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients. Antimicrob Agents Chemother 2020;64:e00513-20. [PMID: 32868333 DOI: 10.1128/AAC.00513-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Humphrey JM, Mpofu P, Pettit AC, Musick B, Carter EJ, Messou E, Marcy O, Crabtree-Ramirez B, Yotebieng M, Anastos K, Sterling TR, Yiannoutsos C, Diero L, Wools-Kaloustian K. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. Open Forum Infect Dis 2020;7:ofaa006. [PMID: 32010735 DOI: 10.1093/ofid/ofaa006] [Reference Citation Analysis]
16 Chen J, Han YS, Yi WJ, Huang H, Li ZB, Shi LY, Wei LL, Yu Y, Jiang TT, Li JC. Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug-resistant tuberculosis based on data-independent acquisition and targeted proteomics. J Cell Mol Med 2020;24:12537-49. [PMID: 32967043 DOI: 10.1111/jcmm.15796] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Arinaminpathy N, Gomez GB, Sachdeva KS, Rao R, Parmar M, Nair SA, Rade K, Kumta S, Hermann D, Hanson C, Chin DP, Dewan P. The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis. PLoS One 2020;15:e0230808. [PMID: 32218585 DOI: 10.1371/journal.pone.0230808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Cheng N, Wu S, Luo X, Xu C, Lou Q, Zhu J, You L, Li B. A Comparative Study of Chest Computed Tomography Findings: 1030 Cases of Drug-Sensitive Tuberculosis versus 516 Cases of Drug-Resistant Tuberculosis. Infect Drug Resist 2021;14:1115-28. [PMID: 33776457 DOI: 10.2147/IDR.S300754] [Reference Citation Analysis]